Diabetes product integration
This article was originally published in The Gray Sheet
Roche's goal of creating an artificial pancreas "sometime between 2008 and 2010" trumps short-term objective of being first to market with a continuous blood glucose measuring device, though such a monitor will begin clinical testing this year, von Prondzynski suggests Feb. 4. "Will we beat the competitors? Probably not. I don't think first to market is the most important thing here. I think what matters is quality," he offers. Roche forecasts successful FDA re-inspection of Disetronic unit's Burgdorf, Switzerland facility for late Q2, enabling firm to launch Minitron next-gen insulin pump in the U.S. by Q4. Roche will "take advantage of this year" as competitors Abbott and TheraSense will be pre-occupied with aligning their manufacturing capacity, von Prondzynski tells "The Gray Sheet"...
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.